These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 25249803)
1. Diabetic nephropathy for the primary care provider: new understandings on early detection and treatment. Kowalski A; Krikorian A; Lerma EV Ochsner J; 2014; 14(3):369-79. PubMed ID: 25249803 [TBL] [Abstract][Full Text] [Related]
3. Optimal strategies for identifying kidney disease in diabetes: properties of screening tests, progression of renal dysfunction and impact of treatment - systematic review and modelling of progression and cost-effectiveness. Farmer AJ; Stevens R; Hirst J; Lung T; Oke J; Clarke P; Glasziou P; Neil A; Dunger D; M Colhoun H; Pugh C; Wong G; Perera R; Shine B Health Technol Assess; 2014 Feb; 18(14):1-128. PubMed ID: 24576414 [TBL] [Abstract][Full Text] [Related]
4. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy. Pathak JV; Dass EE Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic approaches to slowing the progression of diabetic nephropathy - is less best? Vivian E; Mannebach C Drugs Context; 2013 Mar; 2013():212249. PubMed ID: 24432038 [TBL] [Abstract][Full Text] [Related]
6. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy. Jacobsen P; Rossing K; Parving HH Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491 [TBL] [Abstract][Full Text] [Related]
9. The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Hackam DG; Khan NA; Hemmelgarn BR; Rabkin SW; Touyz RM; Campbell NR; Padwal R; Campbell TS; Lindsay MP; Hill MD; Quinn RR; Mahon JL; Herman RJ; Schiffrin EL; Ruzicka M; Larochelle P; Feldman RD; Lebel M; Poirier L; Arnold JM; Moe GW; Howlett JG; Trudeau L; Bacon SL; Petrella RJ; Milot A; Stone JA; Drouin D; Boulanger JM; Sharma M; Hamet P; Fodor G; Dresser GK; Carruthers SG; Pylypchuk G; Burgess ED; Burns KD; Vallée M; Prasad GV; Gilbert RE; Leiter LA; Jones C; Ogilvie RI; Woo V; McFarlane PA; Hegele RA; Tobe SW; Can J Cardiol; 2010 May; 26(5):249-58. PubMed ID: 20485689 [TBL] [Abstract][Full Text] [Related]
10. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. Parving HH; Andersen S; Jacobsen P; Christensen PK; Rossing K; Hovind P; Rossing P; Tarnow L Semin Nephrol; 2004 Mar; 24(2):147-57. PubMed ID: 15017527 [TBL] [Abstract][Full Text] [Related]
11. Diabetic nephropathy--the family physician's role. Roett MA; Liegl S; Jabbarpour Y Am Fam Physician; 2012 May; 85(9):883-9. PubMed ID: 22612183 [TBL] [Abstract][Full Text] [Related]
12. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. Khan NA; Hemmelgarn B; Herman RJ; Bell CM; Mahon JL; Leiter LA; Rabkin SW; Hill MD; Padwal R; Touyz RM; Larochelle P; Feldman RD; Schiffrin EL; Campbell NR; Moe G; Prasad R; Arnold MO; Campbell TS; Milot A; Stone JA; Jones C; Ogilvie RI; Hamet P; Fodor G; Carruthers G; Burns KD; Ruzicka M; DeChamplain J; Pylypchuk G; Petrella R; Boulanger JM; Trudeau L; Hegele RA; Woo V; McFarlane P; Vallée M; Howlett J; Bacon SL; Lindsay P; Gilbert RE; Lewanczuk RZ; Tobe S; Can J Cardiol; 2009 May; 25(5):287-98. PubMed ID: 19417859 [TBL] [Abstract][Full Text] [Related]
13. Is antihypertensive treatment the same for NIDDM and IDDM patients? Parving HH Diabetes Res Clin Pract; 1998 Apr; 39 Suppl():S43-7. PubMed ID: 9649959 [TBL] [Abstract][Full Text] [Related]
14. ACE inhibitor and angiotensin II type 1 receptor antagonist therapies in elderly patients with diabetes mellitus: are they underutilized? Pappoe LS; Winkelmayer WC Drugs Aging; 2010 Feb; 27(2):87-94. PubMed ID: 20104936 [TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus. Hughes DB; Britton ML Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors. Crook ED; Preddie DC Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155 [TBL] [Abstract][Full Text] [Related]
17. [Risk and prevention of diabetic nephropathy]. Ravera M; Re M; Deferrari G G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442 [TBL] [Abstract][Full Text] [Related]
18. Treatment of diabetic nephropathy with angiotensin II receptor antagonist. Lewis EJ; Lewis JB Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737 [TBL] [Abstract][Full Text] [Related]
19. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154 [TBL] [Abstract][Full Text] [Related]